Related Experiment Video
Updated: Apr 3, 2026

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
Published on: July 20, 2022
Antibiotic Impregnated External Ventricular Drains: Meta and Cost Analysis
Brandon K Root1, Benjamin G Barrena2, Todd A Mackenzie2
1Section of Neurosurgery, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, New Hampshire, USA.
Antibiotic-impregnated external ventricular drains (AI-EVDs) significantly reduce ventriculostomy-associated infections (VAI). These AI-EVDs are also cost-effective, offering substantial savings for hospitals by preventing VAI.
Area of Science:
- Neurosurgery
- Infectious Disease Prevention
- Health Economics
Background:
- Ventriculostomy-associated infections (VAI) pose a significant risk to patients requiring external ventricular drains (EVDs).
- The efficacy and cost-effectiveness of antibiotic-impregnated EVDs (AI-EVDs) in preventing VAI remain areas of active investigation.
Purpose of the Study:
- To evaluate the effectiveness of AI-EVDs in preventing VAI.
- To assess the cost-effectiveness of utilizing AI-EVDs compared to standard EVDs.
Main Methods:
- A systematic literature search identified randomized controlled trials and observational cohort studies comparing AI-EVDs with non-impregnated controls.
- A random effects meta-analysis was conducted on the pooled data.
- Institutional historical data were used to calculate incremental costs and VAI-associated hospital expenses.
Main Results:
- The meta-analysis included 3 RCTs and 5 observational studies, demonstrating a significant protective effect of AI-EVDs against VAI (Risk Ratio = 0.31).
- The number needed to treat (NNT) with AI-EVDs to prevent one VAI was 19.
- AI-EVDs are projected to save an estimated $28,100 per NNT, with potential annual savings ranging from $109,292 to $278,577 for hospitals using 150 annually.
Conclusions:
- AI-EVDs offer a statistically significant reduction in VAI.
- The use of AI-EVDs is associated with considerable cost savings for healthcare institutions.
- While current data support the efficacy and cost-effectiveness of AI-EVDs, further research is warranted due to limited available data.
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Acute Pyelonephritis II: Diagnostic Studies and Management
Automated Microbial Diagnostics
